CA2464735C - An albuterol and ipratropium inhalation solution, system, kit and method for relieving symptoms of chronic obstructive pulmonary disease - Google Patents
An albuterol and ipratropium inhalation solution, system, kit and method for relieving symptoms of chronic obstructive pulmonary disease Download PDFInfo
- Publication number
- CA2464735C CA2464735C CA2464735A CA2464735A CA2464735C CA 2464735 C CA2464735 C CA 2464735C CA 2464735 A CA2464735 A CA 2464735A CA 2464735 A CA2464735 A CA 2464735A CA 2464735 C CA2464735 C CA 2464735C
- Authority
- CA
- Canada
- Prior art keywords
- inhalation solution
- albuterol
- solution
- inhalation
- containers
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- 229940041682 inhalant solution Drugs 0.000 title claims abstract description 174
- NDAUXUAQIAJITI-UHFFFAOYSA-N albuterol Chemical compound CC(C)(C)NCC(O)C1=CC=C(O)C(CO)=C1 NDAUXUAQIAJITI-UHFFFAOYSA-N 0.000 title claims abstract description 129
- 229960002052 salbutamol Drugs 0.000 title claims abstract description 126
- 208000006545 Chronic Obstructive Pulmonary Disease Diseases 0.000 title claims abstract description 80
- 238000000034 method Methods 0.000 title claims abstract description 67
- OEXHQOGQTVQTAT-JRNQLAHRSA-N ipratropium Chemical compound O([C@H]1C[C@H]2CC[C@@H](C1)[N@@+]2(C)C(C)C)C(=O)C(CO)C1=CC=CC=C1 OEXHQOGQTVQTAT-JRNQLAHRSA-N 0.000 title claims description 80
- 229960001888 ipratropium Drugs 0.000 title claims description 78
- 208000024891 symptom Diseases 0.000 title claims description 25
- 206010006482 Bronchospasm Diseases 0.000 claims abstract description 36
- 229960001361 ipratropium bromide Drugs 0.000 claims abstract description 36
- KEWHKYJURDBRMN-ZEODDXGYSA-M ipratropium bromide hydrate Chemical compound O.[Br-].O([C@H]1C[C@H]2CC[C@@H](C1)[N@@+]2(C)C(C)C)C(=O)C(CO)C1=CC=CC=C1 KEWHKYJURDBRMN-ZEODDXGYSA-M 0.000 claims abstract description 33
- 208000009079 Bronchial Spasm Diseases 0.000 claims abstract description 32
- 208000014181 Bronchial disease Diseases 0.000 claims abstract description 32
- 229960000686 benzalkonium chloride Drugs 0.000 claims abstract description 18
- CADWTSSKOVRVJC-UHFFFAOYSA-N benzyl(dimethyl)azanium;chloride Chemical compound [Cl-].C[NH+](C)CC1=CC=CC=C1 CADWTSSKOVRVJC-UHFFFAOYSA-N 0.000 claims abstract description 18
- FYTIZSKUAAWPPR-UHFFFAOYSA-M [Br-].CC(C)(C)NCC(O)C1=CC=C(O)C(CO)=C1.CC(C)[N+]1(C)C(C2)CCC1CC2OC(=O)C(CO)C1=CC=CC=C1 Chemical compound [Br-].CC(C)(C)NCC(O)C1=CC=C(O)C(CO)=C1.CC(C)[N+]1(C)C(C2)CCC1CC2OC(=O)C(CO)C1=CC=CC=C1 FYTIZSKUAAWPPR-UHFFFAOYSA-M 0.000 claims abstract description 10
- 230000000845 anti-microbial effect Effects 0.000 claims abstract 5
- 239000003755 preservative agent Substances 0.000 claims abstract 5
- 239000000203 mixture Substances 0.000 claims description 43
- 239000000243 solution Substances 0.000 claims description 37
- 235000002639 sodium chloride Nutrition 0.000 claims description 33
- 206010067484 Adverse reaction Diseases 0.000 claims description 29
- 230000006838 adverse reaction Effects 0.000 claims description 29
- 150000003839 salts Chemical class 0.000 claims description 22
- 239000003795 chemical substances by application Substances 0.000 claims description 21
- 239000003814 drug Substances 0.000 claims description 21
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 claims description 20
- 229940057282 albuterol sulfate Drugs 0.000 claims description 19
- BNPSSFBOAGDEEL-UHFFFAOYSA-N albuterol sulfate Chemical compound OS(O)(=O)=O.CC(C)(C)NCC(O)C1=CC=C(O)C(CO)=C1.CC(C)(C)NCC(O)C1=CC=C(O)C(CO)=C1 BNPSSFBOAGDEEL-UHFFFAOYSA-N 0.000 claims description 19
- 230000003204 osmotic effect Effects 0.000 claims description 18
- 230000001954 sterilising effect Effects 0.000 claims description 18
- 230000001225 therapeutic effect Effects 0.000 claims description 18
- 239000002253 acid Substances 0.000 claims description 17
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 claims description 16
- 238000002663 nebulization Methods 0.000 claims description 14
- 230000002411 adverse Effects 0.000 claims description 13
- 230000007883 bronchodilation Effects 0.000 claims description 13
- 206010020751 Hypersensitivity Diseases 0.000 claims description 12
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 12
- 201000007100 Pharyngitis Diseases 0.000 claims description 11
- 239000007857 degradation product Substances 0.000 claims description 11
- 238000003860 storage Methods 0.000 claims description 11
- CPELXLSAUQHCOX-UHFFFAOYSA-M Bromide Chemical compound [Br-] CPELXLSAUQHCOX-UHFFFAOYSA-M 0.000 claims description 10
- 208000010201 Exanthema Diseases 0.000 claims description 10
- 201000005884 exanthem Diseases 0.000 claims description 10
- 206010037844 rash Diseases 0.000 claims description 10
- 239000011780 sodium chloride Substances 0.000 claims description 10
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 claims description 9
- 239000007864 aqueous solution Substances 0.000 claims description 9
- 239000011888 foil Substances 0.000 claims description 9
- WCUXLLCKKVVCTQ-UHFFFAOYSA-M Potassium chloride Chemical compound [Cl-].[K+] WCUXLLCKKVVCTQ-UHFFFAOYSA-M 0.000 claims description 8
- 238000002156 mixing Methods 0.000 claims description 8
- JIAARYAFYJHUJI-UHFFFAOYSA-L zinc dichloride Chemical compound [Cl-].[Cl-].[Zn+2] JIAARYAFYJHUJI-UHFFFAOYSA-L 0.000 claims description 8
- 201000002862 Angle-Closure Glaucoma Diseases 0.000 claims description 7
- 208000026935 allergic disease Diseases 0.000 claims description 7
- 208000010668 atopic eczema Diseases 0.000 claims description 7
- 238000006243 chemical reaction Methods 0.000 claims description 7
- 230000005713 exacerbation Effects 0.000 claims description 7
- 238000011049 filling Methods 0.000 claims description 7
- 230000009610 hypersensitivity Effects 0.000 claims description 7
- 229920001684 low density polyethylene Polymers 0.000 claims description 7
- 239000004702 low-density polyethylene Substances 0.000 claims description 7
- 229930003347 Atropine Natural products 0.000 claims description 6
- 208000008035 Back Pain Diseases 0.000 claims description 6
- 206010006486 Bronchospasm paradoxical Diseases 0.000 claims description 6
- 206010008479 Chest Pain Diseases 0.000 claims description 6
- 206010012735 Diarrhoea Diseases 0.000 claims description 6
- 206010013911 Dysgeusia Diseases 0.000 claims description 6
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 claims description 6
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 6
- 206010015958 Eye pain Diseases 0.000 claims description 6
- RKUNBYITZUJHSG-UHFFFAOYSA-N Hyosciamin-hydrochlorid Natural products CN1C(C2)CCC1CC2OC(=O)C(CO)C1=CC=CC=C1 RKUNBYITZUJHSG-UHFFFAOYSA-N 0.000 claims description 6
- 208000019693 Lung disease Diseases 0.000 claims description 6
- 208000007101 Muscle Cramp Diseases 0.000 claims description 6
- 206010028813 Nausea Diseases 0.000 claims description 6
- 206010033557 Palpitations Diseases 0.000 claims description 6
- 206010035664 Pneumonia Diseases 0.000 claims description 6
- 208000037656 Respiratory Sounds Diseases 0.000 claims description 6
- 206010057190 Respiratory tract infections Diseases 0.000 claims description 6
- 206010041349 Somnolence Diseases 0.000 claims description 6
- 206010046306 Upper respiratory tract infection Diseases 0.000 claims description 6
- 206010047513 Vision blurred Diseases 0.000 claims description 6
- 206010047924 Wheezing Diseases 0.000 claims description 6
- 230000001154 acute effect Effects 0.000 claims description 6
- 229960000396 atropine Drugs 0.000 claims description 6
- 206010006451 bronchitis Diseases 0.000 claims description 6
- 201000006549 dyspepsia Diseases 0.000 claims description 6
- 238000011010 flushing procedure Methods 0.000 claims description 6
- 230000001939 inductive effect Effects 0.000 claims description 6
- 230000008693 nausea Effects 0.000 claims description 6
- 238000001556 precipitation Methods 0.000 claims description 6
- 201000009890 sinusitis Diseases 0.000 claims description 6
- 208000019206 urinary tract infection Diseases 0.000 claims description 6
- 206010002198 Anaphylactic reaction Diseases 0.000 claims description 5
- 208000028185 Angioedema Diseases 0.000 claims description 5
- 206010030113 Oedema Diseases 0.000 claims description 5
- 206010068319 Oropharyngeal pain Diseases 0.000 claims description 5
- 208000003251 Pruritus Diseases 0.000 claims description 5
- 206010045240 Type I hypersensitivity Diseases 0.000 claims description 5
- 208000024780 Urticaria Diseases 0.000 claims description 5
- 230000036783 anaphylactic response Effects 0.000 claims description 5
- 208000003455 anaphylaxis Diseases 0.000 claims description 5
- 238000004519 manufacturing process Methods 0.000 claims description 5
- 231100000046 skin rash Toxicity 0.000 claims description 5
- UXVMQQNJUSDDNG-UHFFFAOYSA-L Calcium chloride Chemical compound [Cl-].[Cl-].[Ca+2] UXVMQQNJUSDDNG-UHFFFAOYSA-L 0.000 claims description 4
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 claims description 4
- 229910052782 aluminium Inorganic materials 0.000 claims description 4
- 239000001110 calcium chloride Substances 0.000 claims description 4
- 229910001628 calcium chloride Inorganic materials 0.000 claims description 4
- 235000011148 calcium chloride Nutrition 0.000 claims description 4
- 239000001103 potassium chloride Substances 0.000 claims description 4
- 235000011164 potassium chloride Nutrition 0.000 claims description 4
- 239000008213 purified water Substances 0.000 claims description 4
- 238000007789 sealing Methods 0.000 claims description 4
- 239000011592 zinc chloride Substances 0.000 claims description 4
- 235000005074 zinc chloride Nutrition 0.000 claims description 4
- VBSTXRUAXCTZBQ-UHFFFAOYSA-N 1-hexyl-4-phenylpiperazine Chemical compound C1CN(CCCCCC)CCN1C1=CC=CC=C1 VBSTXRUAXCTZBQ-UHFFFAOYSA-N 0.000 claims description 3
- ONPJWQSDZCGSQM-UHFFFAOYSA-N 2-phenylprop-2-enoic acid Chemical compound OC(=O)C(=C)C1=CC=CC=C1 ONPJWQSDZCGSQM-UHFFFAOYSA-N 0.000 claims description 3
- AWYDXHUMBDRXQO-UHFFFAOYSA-N 4-[2-(tert-butylamino)-1-hydroxyethyl]-2-(methoxymethyl)phenol Chemical compound COCC1=CC(C(O)CNC(C)(C)C)=CC=C1O AWYDXHUMBDRXQO-UHFFFAOYSA-N 0.000 claims description 3
- GELQRPHSNNCPNQ-UHFFFAOYSA-N 4-[2-(tert-butylamino)-1-hydroxyethyl]-2-methylphenol Chemical compound CC1=CC(C(O)CNC(C)(C)C)=CC=C1O GELQRPHSNNCPNQ-UHFFFAOYSA-N 0.000 claims description 3
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 claims description 3
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 claims description 3
- 229930195725 Mannitol Natural products 0.000 claims description 3
- JACRWUWPXAESPB-QMMMGPOBSA-N Tropic acid Natural products OC[C@H](C(O)=O)C1=CC=CC=C1 JACRWUWPXAESPB-QMMMGPOBSA-N 0.000 claims description 3
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 claims description 3
- 239000008121 dextrose Substances 0.000 claims description 3
- 229940124274 edetate disodium Drugs 0.000 claims description 3
- 239000000594 mannitol Substances 0.000 claims description 3
- 235000010355 mannitol Nutrition 0.000 claims description 3
- 239000004033 plastic Substances 0.000 claims description 3
- 229920003023 plastic Polymers 0.000 claims description 3
- 229910001220 stainless steel Inorganic materials 0.000 claims description 3
- 239000010935 stainless steel Substances 0.000 claims description 3
- 238000004659 sterilization and disinfection Methods 0.000 claims description 3
- 230000000172 allergic effect Effects 0.000 claims description 2
- 239000002357 osmotic agent Substances 0.000 claims description 2
- 230000015556 catabolic process Effects 0.000 claims 4
- 238000006731 degradation reaction Methods 0.000 claims 4
- 230000002335 preservative effect Effects 0.000 claims 4
- VORSMCHHJRVORT-UHFFFAOYSA-N (8-propan-2-yl-8-azabicyclo[3.2.1]octan-3-yl) 3-hydroxy-2-phenylpropanoate Chemical compound CC(C)N1C(C2)CCC1CC2OC(=O)C(CO)C1=CC=CC=C1 VORSMCHHJRVORT-UHFFFAOYSA-N 0.000 claims 2
- RKUWGGWMRHKETC-UHFFFAOYSA-N 4-[2-(tert-butylamino)-1-hydroxyethyl]-2-chloro-6-(hydroxymethyl)phenol Chemical compound CC(C)(C)NCC(O)C1=CC(Cl)=C(O)C(CO)=C1 RKUWGGWMRHKETC-UHFFFAOYSA-N 0.000 claims 2
- RDOXTESZEPMUJZ-UHFFFAOYSA-N anisole Chemical compound COC1=CC=CC=C1 RDOXTESZEPMUJZ-UHFFFAOYSA-N 0.000 claims 2
- 238000004806 packaging method and process Methods 0.000 claims 2
- ZGTMUACCHSMWAC-UHFFFAOYSA-L EDTA disodium salt (anhydrous) Chemical compound [Na+].[Na+].OC(=O)CN(CC([O-])=O)CCN(CC(O)=O)CC([O-])=O ZGTMUACCHSMWAC-UHFFFAOYSA-L 0.000 claims 1
- 239000013011 aqueous formulation Substances 0.000 claims 1
- 238000009740 moulding (composite fabrication) Methods 0.000 claims 1
- 238000012859 sterile filling Methods 0.000 claims 1
- 229940124630 bronchodilator Drugs 0.000 abstract description 8
- 230000009977 dual effect Effects 0.000 abstract description 3
- 239000006199 nebulizer Substances 0.000 description 32
- 238000011282 treatment Methods 0.000 description 23
- 229940079593 drug Drugs 0.000 description 20
- 230000000694 effects Effects 0.000 description 8
- 238000009472 formulation Methods 0.000 description 6
- 238000002483 medication Methods 0.000 description 6
- 230000008569 process Effects 0.000 description 6
- 239000000126 substance Substances 0.000 description 6
- 230000000670 limiting effect Effects 0.000 description 5
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 4
- 230000008901 benefit Effects 0.000 description 4
- 230000007885 bronchoconstriction Effects 0.000 description 4
- 150000001875 compounds Chemical class 0.000 description 4
- 239000005022 packaging material Substances 0.000 description 4
- 239000002245 particle Substances 0.000 description 4
- ZFXYFBGIUFBOJW-UHFFFAOYSA-N theophylline Chemical compound O=C1N(C)C(=O)N(C)C2=C1NC=N2 ZFXYFBGIUFBOJW-UHFFFAOYSA-N 0.000 description 4
- 238000002560 therapeutic procedure Methods 0.000 description 4
- 241001550224 Apha Species 0.000 description 3
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 3
- IMNFDUFMRHMDMM-UHFFFAOYSA-N N-Heptane Chemical compound CCCCCCC IMNFDUFMRHMDMM-UHFFFAOYSA-N 0.000 description 3
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 3
- 230000001684 chronic effect Effects 0.000 description 3
- 239000000356 contaminant Substances 0.000 description 3
- 238000003745 diagnosis Methods 0.000 description 3
- 238000007865 diluting Methods 0.000 description 3
- 230000007717 exclusion Effects 0.000 description 3
- 239000007789 gas Substances 0.000 description 3
- 230000004048 modification Effects 0.000 description 3
- 238000012986 modification Methods 0.000 description 3
- 230000004044 response Effects 0.000 description 3
- RZVAJINKPMORJF-UHFFFAOYSA-N Acetaminophen Chemical compound CC(=O)NC1=CC=C(O)C=C1 RZVAJINKPMORJF-UHFFFAOYSA-N 0.000 description 2
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 2
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 2
- 208000036647 Medication errors Diseases 0.000 description 2
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 2
- 239000004480 active ingredient Substances 0.000 description 2
- 239000000443 aerosol Substances 0.000 description 2
- 239000004599 antimicrobial Substances 0.000 description 2
- 230000004888 barrier function Effects 0.000 description 2
- 239000000168 bronchodilator agent Substances 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 238000012864 cross contamination Methods 0.000 description 2
- 238000013461 design Methods 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 231100000673 dose–response relationship Toxicity 0.000 description 2
- -1 halide salts Chemical class 0.000 description 2
- 230000036541 health Effects 0.000 description 2
- 230000006872 improvement Effects 0.000 description 2
- 230000001965 increasing effect Effects 0.000 description 2
- 238000005259 measurement Methods 0.000 description 2
- YKYONYBAUNKHLG-UHFFFAOYSA-N propyl acetate Chemical compound CCCOC(C)=O YKYONYBAUNKHLG-UHFFFAOYSA-N 0.000 description 2
- 230000001681 protective effect Effects 0.000 description 2
- 230000029058 respiratory gaseous exchange Effects 0.000 description 2
- 229960000278 theophylline Drugs 0.000 description 2
- XWTYSIMOBUGWOL-UHFFFAOYSA-N (+-)-Terbutaline Chemical compound CC(C)(C)NCC(O)C1=CC(O)=CC(O)=C1 XWTYSIMOBUGWOL-UHFFFAOYSA-N 0.000 description 1
- ZWEHNKRNPOVVGH-UHFFFAOYSA-N 2-Butanone Chemical compound CCC(C)=O ZWEHNKRNPOVVGH-UHFFFAOYSA-N 0.000 description 1
- RGHHSNMVTDWUBI-UHFFFAOYSA-N 4-hydroxybenzaldehyde Chemical compound OC1=CC=C(C=O)C=C1 RGHHSNMVTDWUBI-UHFFFAOYSA-N 0.000 description 1
- DGGKXQQCVPAUEA-UHFFFAOYSA-N 8-azabicyclo[3.2.1]octane Chemical compound C1CCC2CCC1N2 DGGKXQQCVPAUEA-UHFFFAOYSA-N 0.000 description 1
- 208000020053 Abnormal inflammatory response Diseases 0.000 description 1
- BSYNRYMUTXBXSQ-UHFFFAOYSA-N Aspirin Chemical compound CC(=O)OC1=CC=CC=C1C(O)=O BSYNRYMUTXBXSQ-UHFFFAOYSA-N 0.000 description 1
- 206010003645 Atopy Diseases 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 1
- 206010010774 Constipation Diseases 0.000 description 1
- 206010011224 Cough Diseases 0.000 description 1
- 206010013654 Drug abuse Diseases 0.000 description 1
- 206010013952 Dysphonia Diseases 0.000 description 1
- 206010021143 Hypoxia Diseases 0.000 description 1
- HEFNNWSXXWATRW-UHFFFAOYSA-N Ibuprofen Chemical compound CC(C)CC1=CC=C(C(C)C(O)=O)C=C1 HEFNNWSXXWATRW-UHFFFAOYSA-N 0.000 description 1
- 208000001388 Opportunistic Infections Diseases 0.000 description 1
- 208000002193 Pain Diseases 0.000 description 1
- 101150034459 Parpbp gene Proteins 0.000 description 1
- 208000008601 Polycythemia Diseases 0.000 description 1
- 206010036790 Productive cough Diseases 0.000 description 1
- 208000004756 Respiratory Insufficiency Diseases 0.000 description 1
- 206010039085 Rhinitis allergic Diseases 0.000 description 1
- 206010039163 Right ventricular failure Diseases 0.000 description 1
- GIIZNNXWQWCKIB-UHFFFAOYSA-N Serevent Chemical compound C1=C(O)C(CO)=CC(C(O)CNCCCCCCOCCCCC=2C=CC=CC=2)=C1 GIIZNNXWQWCKIB-UHFFFAOYSA-N 0.000 description 1
- 201000010001 Silicosis Diseases 0.000 description 1
- 208000006011 Stroke Diseases 0.000 description 1
- GUGOEEXESWIERI-UHFFFAOYSA-N Terfenadine Chemical compound C1=CC(C(C)(C)C)=CC=C1C(O)CCCN1CCC(C(O)(C=2C=CC=CC=2)C=2C=CC=CC=2)CC1 GUGOEEXESWIERI-UHFFFAOYSA-N 0.000 description 1
- 206010066901 Treatment failure Diseases 0.000 description 1
- 208000007814 Unstable Angina Diseases 0.000 description 1
- 229960001138 acetylsalicylic acid Drugs 0.000 description 1
- 239000000556 agonist Substances 0.000 description 1
- 201000010105 allergic rhinitis Diseases 0.000 description 1
- 230000000202 analgesic effect Effects 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 150000008064 anhydrides Chemical class 0.000 description 1
- 208000010123 anthracosis Diseases 0.000 description 1
- 230000001088 anti-asthma Effects 0.000 description 1
- 230000001078 anti-cholinergic effect Effects 0.000 description 1
- 230000001387 anti-histamine Effects 0.000 description 1
- 239000000924 antiasthmatic agent Substances 0.000 description 1
- 239000000739 antihistaminic agent Substances 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 229940127225 asthma medication Drugs 0.000 description 1
- 229960001716 benzalkonium Drugs 0.000 description 1
- CYDRXTMLKJDRQH-UHFFFAOYSA-N benzododecinium Chemical compound CCCCCCCCCCCC[N+](C)(C)CC1=CC=CC=C1 CYDRXTMLKJDRQH-UHFFFAOYSA-N 0.000 description 1
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 description 1
- 150000001649 bromium compounds Chemical group 0.000 description 1
- 230000003182 bronchodilatating effect Effects 0.000 description 1
- 239000006227 byproduct Substances 0.000 description 1
- 239000002738 chelating agent Substances 0.000 description 1
- 238000011284 combination treatment Methods 0.000 description 1
- 238000013329 compounding Methods 0.000 description 1
- 230000001276 controlling effect Effects 0.000 description 1
- 238000005520 cutting process Methods 0.000 description 1
- 230000007423 decrease Effects 0.000 description 1
- 230000001079 digestive effect Effects 0.000 description 1
- 230000003467 diminishing effect Effects 0.000 description 1
- 229940000406 drug candidate Drugs 0.000 description 1
- 239000003937 drug carrier Substances 0.000 description 1
- 229940003373 duoneb Drugs 0.000 description 1
- 230000007613 environmental effect Effects 0.000 description 1
- 201000010235 heart cancer Diseases 0.000 description 1
- 208000019622 heart disease Diseases 0.000 description 1
- 208000024348 heart neoplasm Diseases 0.000 description 1
- XMBWDFGMSWQBCA-UHFFFAOYSA-N hydrogen iodide Chemical compound I XMBWDFGMSWQBCA-UHFFFAOYSA-N 0.000 description 1
- 230000007954 hypoxia Effects 0.000 description 1
- 229960001680 ibuprofen Drugs 0.000 description 1
- 230000008676 import Effects 0.000 description 1
- 239000012633 leachable Substances 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 230000004199 lung function Effects 0.000 description 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 1
- 239000003595 mist Substances 0.000 description 1
- 150000004682 monohydrates Chemical class 0.000 description 1
- 230000008450 motivation Effects 0.000 description 1
- 208000010125 myocardial infarction Diseases 0.000 description 1
- 239000002547 new drug Substances 0.000 description 1
- 230000001473 noxious effect Effects 0.000 description 1
- 230000000414 obstructive effect Effects 0.000 description 1
- 229960005489 paracetamol Drugs 0.000 description 1
- 239000013618 particulate matter Substances 0.000 description 1
- 206010035653 pneumoconiosis Diseases 0.000 description 1
- 239000013641 positive control Substances 0.000 description 1
- 230000035935 pregnancy Effects 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 230000000750 progressive effect Effects 0.000 description 1
- 230000005180 public health Effects 0.000 description 1
- 230000002685 pulmonary effect Effects 0.000 description 1
- 230000002829 reductive effect Effects 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 201000004193 respiratory failure Diseases 0.000 description 1
- 208000023504 respiratory system disease Diseases 0.000 description 1
- 230000002441 reversible effect Effects 0.000 description 1
- 229960004017 salmeterol Drugs 0.000 description 1
- 230000000391 smoking effect Effects 0.000 description 1
- 239000012453 solvate Substances 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 238000013125 spirometry Methods 0.000 description 1
- 208000024794 sputum Diseases 0.000 description 1
- 210000003802 sputum Anatomy 0.000 description 1
- 208000011117 substance-related disease Diseases 0.000 description 1
- IWOKCMBOJXYDEE-UHFFFAOYSA-N sulfinylmethane Chemical compound C=S=O IWOKCMBOJXYDEE-UHFFFAOYSA-N 0.000 description 1
- 150000003467 sulfuric acid derivatives Chemical class 0.000 description 1
- UXQPRXPNOJXOQO-UHFFFAOYSA-N sulfuric acid;hydrobromide Chemical compound Br.OS(O)(=O)=O UXQPRXPNOJXOQO-UHFFFAOYSA-N 0.000 description 1
- 230000002123 temporal effect Effects 0.000 description 1
- 229960000195 terbutaline Drugs 0.000 description 1
- 125000006318 tert-butyl amino group Chemical group [H]N(*)C(C([H])([H])[H])(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 208000014001 urinary system disease Diseases 0.000 description 1
- 239000003981 vehicle Substances 0.000 description 1
- 239000003039 volatile agent Substances 0.000 description 1
- 239000002699 waste material Substances 0.000 description 1
- 229940124631 β2-adrenergic bronchodilator Drugs 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/007—Pulmonary tract; Aromatherapy
- A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
- A61K9/0078—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a nebulizer such as a jet nebulizer, ultrasonic nebulizer, e.g. in the form of aqueous drug solutions or dispersions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/08—Bronchodilators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pulmonology (AREA)
- Epidemiology (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Dispersion Chemistry (AREA)
- Otolaryngology (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (9)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US34607801P | 2001-10-26 | 2001-10-26 | |
| US60/346,078 | 2001-10-26 | ||
| US10/034,657 | 2001-12-27 | ||
| US3465701A | 2001-12-28 | 2001-12-28 | |
| AU32974/02A AU3297402A (en) | 2001-10-26 | 2002-04-05 | An albuterol and ipratropium inhalation solution, system, kit and method for relieving symptoms of chronic obstructive pulmonary disease |
| AU32974/02 | 2002-04-05 | ||
| JP2002-158304 | 2002-04-23 | ||
| JP2002158304A JP2003221335A (ja) | 2001-10-26 | 2002-04-23 | 慢性閉塞性肺疾患の症状を緩和するためのアルブテロールおよびイプラトロピウム吸入溶液、システム、キットおよび方法 |
| PCT/US2002/033353 WO2003037159A2 (en) | 2001-10-26 | 2002-10-18 | An albuterol and ipratropium inhalation solution, system, kit and method for relieving symptoms of chronic obstructive pulmonary disease |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CA2464735A1 CA2464735A1 (en) | 2003-05-08 |
| CA2464735C true CA2464735C (en) | 2011-03-22 |
Family
ID=27422968
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA2464735A Expired - Fee Related CA2464735C (en) | 2001-10-26 | 2002-10-18 | An albuterol and ipratropium inhalation solution, system, kit and method for relieving symptoms of chronic obstructive pulmonary disease |
Country Status (8)
| Country | Link |
|---|---|
| EP (1) | EP1446045A4 (de) |
| JP (1) | JP2006505486A (de) |
| CN (2) | CN1939279A (de) |
| AU (1) | AU3297402A (de) |
| CA (1) | CA2464735C (de) |
| MX (1) | MXPA04003927A (de) |
| NZ (1) | NZ552548A (de) |
| WO (1) | WO2003037159A2 (de) |
Families Citing this family (30)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1915985A1 (de) * | 2003-03-20 | 2008-04-30 | Boehringer Ingelheim Pharmaceuticals Inc. | Formulierung für einen Dosierinhalator mit Hydrofluoralkanen als Treibstoffen |
| GB0501956D0 (en) * | 2005-01-31 | 2005-03-09 | Arrow Internat | Nebulizer formulation |
| JP2009537570A (ja) * | 2006-05-18 | 2009-10-29 | ティカ レーケメデル アーベー | アルブテロールの吸入可能溶液を有する単位用量製剤 |
| EP2026784A1 (de) * | 2006-05-19 | 2009-02-25 | Boehringer Ingelheim International GmbH | Aerosolformulierung enthaltend ipratropiumbromid und salbutamolsulfat |
| WO2007134967A1 (de) * | 2006-05-19 | 2007-11-29 | Boehringer Ingelheim International Gmbh | Treibgasfreie aerosolformulierung für die inhalation enthaltend ipratropiumbromid und salbutamolsulfat |
| EP2077132A1 (de) | 2008-01-02 | 2009-07-08 | Boehringer Ingelheim Pharma GmbH & Co. KG | Abgabevorrichtung, Aufbewahrungsvorrichtung und Verfahren zur Abgabe einer Formulierung |
| EP2414560B1 (de) | 2009-03-31 | 2013-10-23 | Boehringer Ingelheim International GmbH | Verfahren zur beschichtung einer oberfläche eines bauteils |
| JP5763053B2 (ja) | 2009-05-18 | 2015-08-12 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | アダプタ、吸入器具及びアトマイザ |
| WO2011064163A1 (en) | 2009-11-25 | 2011-06-03 | Boehringer Ingelheim International Gmbh | Nebulizer |
| US10016568B2 (en) | 2009-11-25 | 2018-07-10 | Boehringer Ingelheim International Gmbh | Nebulizer |
| BR112012012475B1 (pt) | 2009-11-25 | 2020-03-03 | Boehringer Ingelheim International Gmbh | Nebulizador |
| WO2011160932A1 (en) | 2010-06-24 | 2011-12-29 | Boehringer Ingelheim International Gmbh | Nebulizer |
| WO2012106382A1 (en) * | 2011-01-31 | 2012-08-09 | Genoa Pharmaceuticals, Inc. | Aerosol pirfenidone and pyridone analog compounds and uses thereof |
| EP2694220B1 (de) | 2011-04-01 | 2020-05-06 | Boehringer Ingelheim International GmbH | Medizinisches gerät mit behälter |
| US9827384B2 (en) | 2011-05-23 | 2017-11-28 | Boehringer Ingelheim International Gmbh | Nebulizer |
| WO2013152894A1 (de) | 2012-04-13 | 2013-10-17 | Boehringer Ingelheim International Gmbh | Zerstäuber mit kodiermitteln |
| JP6643231B2 (ja) | 2013-08-09 | 2020-02-12 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | ネブライザ |
| ES2836977T3 (es) | 2013-08-09 | 2021-06-28 | Boehringer Ingelheim Int | Nebulizador |
| HK1212903A1 (zh) * | 2013-11-22 | 2016-06-24 | Teva Branded Pharmaceutical Products R & D, Inc. | 可吸入藥物 |
| TR201911194T4 (tr) * | 2013-11-22 | 2019-08-21 | Teva Branded Pharmaceutical Products R&D Inc | Solunabilir bir ilaç. |
| WO2015169430A1 (en) | 2014-05-07 | 2015-11-12 | Boehringer Ingelheim International Gmbh | Nebulizer |
| CN116036425A (zh) | 2014-05-07 | 2023-05-02 | 勃林格殷格翰国际有限公司 | 喷雾器、指示器装置及容器 |
| IL247927B (en) | 2014-05-07 | 2022-09-01 | Boehringer Ingelheim Int | Container, a device that turns a liquid into a fine spray and use |
| JP6771327B2 (ja) * | 2016-07-11 | 2020-10-21 | ファーマパック株式会社 | 薬液容器 |
| CN106344544A (zh) * | 2016-08-25 | 2017-01-25 | 杭州百诚医药科技股份有限公司 | 一种用于治疗支气管哮喘的雾化吸入制剂 |
| CN110898042B (zh) * | 2019-12-12 | 2020-10-16 | 深圳大佛药业股份有限公司 | 一种吸入用硫酸沙丁胺醇溶液剂及其制备方法 |
| CN111053761B (zh) * | 2020-01-16 | 2022-05-03 | 杭州旦承医药科技有限公司 | 一种吸入用双膦酸类药物及其制备方法及其在慢性阻塞性肺疾病的用途 |
| CN115209872B (zh) * | 2020-03-19 | 2024-08-02 | 广州谷森制药有限公司 | 含有酒石酸左旋沙丁胺醇的可吸入制剂 |
| CN113018280A (zh) * | 2021-03-01 | 2021-06-25 | 石家庄四药有限公司 | 一种异丙托溴铵吸入用溶液制剂及其制备方法 |
| CN115645381B (zh) * | 2022-10-20 | 2023-05-30 | 深圳大佛药业股份有限公司 | 一种盐酸左沙丁胺醇雾化吸入溶液缓释剂及其制备方法 |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ATE177941T1 (de) * | 1992-12-09 | 1999-04-15 | Boehringer Ingelheim Pharma | Stabilisierte medizinische aerosollösungen |
| DE19653969A1 (de) * | 1996-12-20 | 1998-06-25 | Boehringer Ingelheim Kg | Neue wässrige Arzneimittelzubereitung zur Erzeugung treibgasfreier Aerosole |
| US6247617B1 (en) * | 1999-12-13 | 2001-06-19 | Richard Allen Clyde | Single use container for dispensing separately housed sterile compositions |
-
2002
- 2002-04-05 AU AU32974/02A patent/AU3297402A/en not_active Abandoned
- 2002-10-18 NZ NZ552548A patent/NZ552548A/xx not_active IP Right Cessation
- 2002-10-18 WO PCT/US2002/033353 patent/WO2003037159A2/en not_active Ceased
- 2002-10-18 CA CA2464735A patent/CA2464735C/en not_active Expired - Fee Related
- 2002-10-18 CN CNA2006101077523A patent/CN1939279A/zh active Pending
- 2002-10-18 EP EP02789216A patent/EP1446045A4/de not_active Withdrawn
- 2002-10-18 MX MXPA04003927A patent/MXPA04003927A/es active IP Right Grant
- 2002-10-18 JP JP2003539509A patent/JP2006505486A/ja active Pending
- 2002-10-18 CN CNA028262263A patent/CN1607940A/zh active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| EP1446045A4 (de) | 2010-07-21 |
| CN1939279A (zh) | 2007-04-04 |
| EP1446045A2 (de) | 2004-08-18 |
| WO2003037159A3 (en) | 2003-10-16 |
| CN1607940A (zh) | 2005-04-20 |
| MXPA04003927A (es) | 2005-03-31 |
| WO2003037159A2 (en) | 2003-05-08 |
| AU3297402A (en) | 2003-10-30 |
| JP2006505486A (ja) | 2006-02-16 |
| NZ552548A (en) | 2009-03-31 |
| CA2464735A1 (en) | 2003-05-08 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CA2464735C (en) | An albuterol and ipratropium inhalation solution, system, kit and method for relieving symptoms of chronic obstructive pulmonary disease | |
| US6632842B2 (en) | Albuterol and ipratropium inhalation solution, system, kit and method for relieving symptoms of chronic obstructive pulmonary disease | |
| AU2002347948B2 (en) | Albuterol inhalation solution, system, kit and method for relieving symptoms of pediatric asthma | |
| US20030191151A1 (en) | Albuterol and ipratropium inhalation solution, system, kit and method for relieving symptoms of chronic obstructive pulmonary disease | |
| AU2002347948A1 (en) | Albuterol inhalation solution, system, kit and method for relieving symptoms of pediatric asthma | |
| AU2016264961B2 (en) | Tiotropium inhalation solution for nebulization | |
| US20030203930A1 (en) | Albuterol and ipratropium inhalation solution, system, kit and method for relieving symptoms of chronic obstructive pulmonary disease | |
| US20030140920A1 (en) | Albuterol inhalation soultion, system, kit and method for relieving symptoms of pediatric asthma | |
| AU2006202585B2 (en) | An albuterol and ipratropium inhalation solution, system, kit and method for relieving symptoms of chronic obstructive pulmonary disease | |
| US8084461B2 (en) | Albuterol and ipratropium inhalation solution, system, kit and method for relieving symptoms of chronic obstructive pulmonary disease | |
| US20050175544A1 (en) | Albuterol inhalation solution, system, kit and method for relieving symptoms of pediatric asthma | |
| AU2002353825B2 (en) | An albuterol and ipratropium inhalation solution, system, kit and method for relieving symptoms of chronic obstructive pulmonary disease | |
| IE890881L (en) | Pharmaceutical Compositions | |
| US20190290633A1 (en) | Tiotropium Inhalation Solution for Nebulization | |
| CA2464660C (en) | Albuterol inhalation solution, system, kit and method for relieving symptoms of pediatric asthma | |
| AU2006202584B2 (en) | An albuterol inhalation solution, system, kit and method for relieving symptoms of pediatric asthma | |
| AU2002353825A1 (en) | An albuterol and ipratropium inhalation solution, system, kit and method for relieving symptoms of chronic obstructive pulmonary disease | |
| JP2010184937A (ja) | 慢性閉塞性肺疾患の症状を緩和するためのアルブテロールおよびイプラトロピウム吸入溶液、キット、吸入溶液を中に有する１容器を作成する方法、および、吸入溶液を作成する方法 | |
| AU2018355544A1 (en) | Tiotropium inhalation solution for nebulization |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| EEER | Examination request | ||
| MKLA | Lapsed |
Effective date: 20201019 |